Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections

A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant...

Descripción completa

Detalles Bibliográficos
Autores principales: Rebold, Nicholas, Morrisette, Taylor, Lagnf, Abdalhamid M, Alosaimy, Sara, Holger, Dana, Barber, Katie, Justo, Julie Ann, Antosz, Kayla, Carlson, Travis J, Frens, Jeremy J, Biagi, Mark, Kufel, Wesley D, Moore, William J, Mercuro, Nicholas, Raux, Brian R, Rybak, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661073/
https://www.ncbi.nlm.nih.gov/pubmed/34901302
http://dx.doi.org/10.1093/ofid/ofab554
Descripción
Sumario:A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects.

Ejemplares similares